Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Overview of attention for article published in BMC Cancer, July 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 27 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 3,032 followers.

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. https://t.co/RlXkGoWKQx

16 Jan 2019

Reply Repost Favourite

RT @Senology: Postmenopausal #breast #cancer women with high Ki67 do significantly benefit from #tamoxifen, while those with high mitotic c…

06 Sep 2018

Reply Repost Favourite

Postmenopausal #breast #cancer women with high Ki67 do significantly benefit from #tamoxifen, while those with high mitotic count do not. Mitotic count is a better selection marker for reduced tamoxifen benefit than Ki67 https://t.co/uI8hpTWphu

05 Sep 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.